Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (OTC: HALB) generates a steady stream of news centered on its healthcare technology initiatives, research collaborations, and funding developments. Investors and observers following HALB news can expect updates on traumatic brain injury (TBI) research, PTSD and mental health programs, AI-driven behavioral platforms, and partnerships with medical and technology organizations.
Recent press releases highlight Halberd’s work with Mississippi State University on a proprietary nasal spray intended to mitigate the effects of TBI, including plans for advanced Phase-2 animal studies. News items also cover the company’s acquisition and development of NeuroSense AI, a behavioral intelligence platform that combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered interpretation for preclinical TBI and neurological research.
Another major theme in HALB news is its LDX and WatchDawg programs for PTSD, suicidal ideation, and related mental health challenges, particularly among veterans. Halberd and its partners report pilot study results using LDX-based therapies, nutraceuticals, yoga and meditation, and continuous wearable monitoring via Athena GTX’s technology. Announcements describe plans for larger clinical studies, solicitations for nephrologists and clinicians, and cooperative efforts with Athena Telemedicine Partners, LLC.
News releases also discuss funding and contract developments, including a substantial contract commitment involving Defense Atomics Corporation to support combined CRISPR/nanotechnology stem cell treatment with Halberd’s LDX protocol and WatchDawg monitoring. Readers of HALB news can use this page to follow progress on government contract proposals, private investment efforts, regulatory planning, and technical milestones in AI-powered healthcare platforms.
For anyone tracking HALB stock or its healthcare projects, the news feed provides context on how Halberd’s research programs, partnerships, and technology demonstrations evolve over time.
Halberd (OTC PINK: HALB) issued a shareholder letter highlighting recent developments. The company's Tri-aX™ TBI nasal spray has shown promising results in preclinical studies at Mississippi State University for treating traumatic brain injury (TBI). The Department of Defense (DoD) selected Halberd's pre-proposal and invited a full application for funding up to $700,000 under the Emerging Topics Research Award.
The research will focus on establishing patterns of change in blood and brain biomarkers of injury at different TBI levels. Halberd emphasizes the need for secrecy regarding their proprietary formulation due to competitive concerns. The company plans to submit a detailed proposal by October 3rd and expects a decision within months.
Halberd (OTC: HALB) has announced promising initial results from Phase II testing of its Tri-Ax™ nasal spray for mitigating traumatic brain injury (TBI) effects. The tests, conducted at Mississippi State University, show that higher impact forces lead to step-wise changes in motor activity levels. Importantly, TBI-induced motor activity changes were significantly improved when Tri-Ax™ was administered one hour post-impact at one of the higher impact forces.
The company sees potential applications in military and civilian contact sports, law enforcement, hospitals, and emergency response units. Halberd is also developing an auto-nasal injector with partner Athena GTX for point-of-injury care. The market potential is considered substantial if ongoing tests continue to support initial optimism.
Halberd (HALB), in collaboration with Athena GTX, is progressing toward innovative treatments for depression, anxiety, substance use disorders, and PTSD, conditions prevalent in both the general population and military. With statistics showing 93,000 suicides yearly in the Americas, the urgency for effective solutions is clear. Halberd’s work includes the patented LDN+ (Low Dose Naltrexone and Cyclobenzaprine), which has shown promise in enhancing opioid receptor function and reducing inflammation. Their Watchdawg™ program integrates pharmacological interventions with psychological support and therapies like yoga. Additionally, their nasal spray for PTSD and TBI has demonstrated potential in reducing neuro-degenerative markers by over 50% in animal studies. This collaboration aims to address significant gaps in current treatment methods and offers hope for improved mental health solutions globally.
Halberd 's two active programs for traumatic brain injury treatment align with the new U.S. House bill aiming to reduce veteran suicide. The company's patented drug LDN+ and nasal spray show promise in treating PTSD, suicide ideation, and addiction. The bill, named after two Marines lost to suicide, aims to provide mental health support for transitioning veterans.
Halberd has initiated pre-pilot trials with military veterans for its patented LDN+ drug, designed to combat PTSD and suicidal ideation. The drug aims to address PTSD and suicidal thoughts by acting as an antagonist against chemical and alcohol use disorders, while also relieving pain and anxiety. The trials involve initial participants, with plans for wider pilot and safety studies in the near future. Halberd will provide updates as the clinical trial progresses.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
